新股消息 | 靖因药业递表港交所 以siRNA疗法赋能慢性病管理范式转变

Core Insights - Jingyin Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with Goldman Sachs, Haitong International, and HSBC acting as joint sponsors [1] Company Overview - Jingyin Pharmaceutical is a global clinical-stage biotechnology company focused on maximizing the clinical and commercial value of siRNA therapies. The company aims to develop innovative and best-in-class siRNA therapies to address significant unmet medical needs in chronic disease management [4][5] - The company is advancing three major product pipelines targeting coagulation disorders, cardiovascular metabolic diseases, and obesity, which are based on their substantial market potential and the ability to provide transformative siRNA solutions [5] Market Potential - According to a Frost & Sullivan report, the global siRNA therapy market is projected to reach USD 2.4 billion in 2024 and grow to USD 50.3 billion by 2040, with a compound annual growth rate (CAGR) of 20.9% [4] Product Pipeline - The core product, SRSD107, is a potential first-in-class siRNA drug targeting coagulation factor XI, currently undergoing Phase II multi-center clinical trials in Europe, with plans for additional trials in China and Australia/New Zealand [5] - SRSD216 is a potential best-in-class siRNA targeting Lp(a), currently in Phase IIa trials in China and the United States [5] - SRSD384 is an INHBE-targeted candidate for obesity, with promising preclinical data and active IND application progress [5] Technology Platform - The company has developed a proprietary PEPR platform that enhances the stability and target binding of siRNA, enabling more effective and durable therapies. Research is ongoing to expand the delivery range of siRNA beyond the liver to other tissues such as fat, skeletal muscle, heart, kidneys, and the central nervous system [6] Financial Performance - For the six months ending June 30, 2023, the company reported other income and revenue of approximately RMB 8.81 million, with a net loss of approximately RMB 309.41 million. The projected other income and revenue for the same period in 2024 is RMB 9.79 million, with an expected loss of RMB 341.96 million [6][7]